Looking for volunteers
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
NCT07182279 · The Methodist Hospital Research Institute · Updated 9 March 2026
- What is being tested
- Brachytherapy
- For
- Prostate Cancer (Adenocarcinoma)
- Kind of study
- Tests a treatment or device on volunteers. Phase 1 and Phase 2.
- Who can join
- Ages 40 years and older. About 29 people. The full rules are on the registry page.
- Where
- United States
- When
- Starts or started 1 Aug 2025, ends 14 Nov 2026. Registered 19 Sept 2025.
- Results
- None posted yet.
In the researchers' words
This is a Phase I/II trial evaluating the effectiveness of adding neoadjuvant HDR-B prior to RALP for HR-PCa patients with selective AAB for decipher high risk or pathologically node positive patients. Patients with newly diagnosed, histologically confirmed, non-metastatic, HR-PCa who are scheduled to receive RALP will be eligible to participate in the study.
Sites
- Houston MethodistHouston, Texas, United States